| Project/Area Number |
24592378
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
MOTOFUMI Suzuki 東京大学, 医学部附属病院, 臨床登録医 (50401063)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SANADA Masashi 京都大学, 医学(系)研究科(研究院), 助教 (20529044)
HOMMA Yukio 東京大学, 医学部附属病院, 教授 (40165626)
OGAWA Seishi 京都大学, 医学(系)研究科(研究院), 教授 (60292900)
SATO Aiko 京都大学, 医学(系)研究科(研究院), 研究員 (70512573)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
ARAI Tomio 東京都健康長寿医療センター, 研究員 (20232019)
|
|---|
| Research Collaborator |
SUZUKI Yutaka 東京大学, 新領域創成科学研究科, 教授 (40323646)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Keywords | 前立腺癌 / 遺伝子解析 / 一塩基多型 |
|---|
| Outline of Final Research Achievements |
We revealed that the TMPRSS2 Met160Val polymorphism was significantly associated with clinical prostate cancer risk in a native Japanese population. Comparing with Val/Val genotype, age-adjusted odds ratios (95% CIs) were 1.418 (1.030-1.956) for Val/Met and 1.906 (1.230-2.979) for Met/Met genotype, respectively. The polymorphism was not associated with the risk of latent prostate cancer.
We also conducted a replication study on 55 genetic polymorphisms that were associated with prostate cancer susceptibility found by genome-wide association studies. We found only 6 polymorphisms that located on chromosome 8 were significant risk factor of clinical prostate cancer in a native Japanese population. These 6 polymorphisms were not associated with the risk of latent prostate cancer, either.
|
